News

Amgen stock bounded above its 50-day line Tuesday after publishing promising results for its experimental Sjogren's treatment.

A private meeting with Amgen management left Morgan Stanley with a very different read than the broader market’s.

Heart disease remains humanity’s top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.

Pre-Market Stock Futures: Futures are trading mixed after a second brutal day, with all major indices finishing lower again. Rising rates, Brent Crude trading above $100, and what appears to be an increase in the Iran attacks in the Persian Gulf were all it took for sellers to keep hitting bids. Once again, the small-cap […]

Investing.com -- HSBC adjusted ratings and target prices across its biopharma coverage, citing "a lower sector additional risk premium" following a rally in the second quarter of 2026.

Here are four highlights of a rocky day in markets Tuesday. Canadian tariffs on U.S. goods kicked in. Oil rose, while stocks fell. Amgen stock shed 10% Howmet Aerospace was the worst performer in the S&P.

📣 “This is the worst possible outcome for Amgen.” —Barclays analyst Emily Field, on Novartis announcing a disappointing result for its heart disease drug, a disclsoure that also cast doubt on one of Amgen's big drugs.

Shares of Amgen were recently down more than 9%, putting the biotechnology company on pace for its largest decrease since October 2000. The decline came after Novartis announced a failure of its heart disease drug, pelacarsen, to reduce the risk of cardiovascular events compared with a placebo. The failure, which sent U.S.-traded Novartis shares down 14%, also cast doubt on similar drugs, including Amgen’s investigational treatment olpasiran.

Major stock indexes faced pressure on Tuesday with a fresh slate of geopolitical tensions weighing on investors. The Dow industrials are down about 1%. Meanwhile, quantum computing stocks are on the rise.

Wall Street returns from summer vacation to a market suddenly bracing for a rate hike, with fresh analyst calls on Intel, Lockheed Martin, Amgen, and SpaceX adding more pressure points to an already tense week.

AI stocks rise despite the market’s inflation worries, but Amgen falls following Swiss drugmaker Novartis’ disappointing trial data.

U.S. markets wobbled as higher oil prices dragged sentiment before investors return from the Labor Day weekend.

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Three catalysts, one reshuffling, and a Fed that refuses to move

Investors rotated toward profitable drugmakers while personalized cancer-vaccine results energized biotechnology stocks.

Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to make a move before pivotal trial data arrives.

President Trump is asking cybersecurity and tech companies to take on a potentially dangerous new role attacking foreign cybercriminals, but the plan offers few incentives to balance the risks. Genetic testing lab Baylor Genetics disclosed a cyber incident where a hacker had access to certain internal systems between June 11 and June 17. An unspecified number of patients had their medical testing and lab results compromised while current and former employees had their Social Security numbers and financial account data exposed, Baylor said.

Picture three students turning in exams on the same day, covering the same material. Two walk away with high marks. The third has been raising his grades all semester, yet still gets flagged for summer school. That is roughly the dynamic inside the BofA research note on biotech I received on the ...

BeOne Medicines Ltd (ONC) delivers robust Q2 2026 results with record BRUKINSA sales, raises full-year guidance, and advances a promising oncology pipeline.

Revenue surged 10% as six growth drivers now fuel 70% of product sales.

Mineralys Therapeutics (NASDAQ:MLYS) said it is continuing commercial-launch preparations for lorundrostat ahead of its December 22 Prescription Drug User Fee Act target date, while reporting a wider second-quarter loss driven largely by a $200 million upfront payment related to its amended agreemen

Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results marked by higher royalty revenue and adjusted earnings, while highlighting the post-quarter close of its XOMA Royalty acquisition and a $700 million zero-coupon convertible-note offering. Total revenue rose 34% year over year

The S&P 500 Index ($SPX ) (SPY ) today is up +0.31%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.05%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.03%. September E-mini S&P futures (ESU26 ) are up +0.33%, and September E-mini Nasdaq futures...

The S&P 500 Index ($SPX ) (SPY ) today is up +0.46%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.74%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.51%. September E-mini S&P futures (ESU26 ) are up +0.50%, and September E-mini Nasdaq futures...

The biotech raised its full-year revenue forecast to $38.2 billion–$39.4 billion after second-quarter revenue rose 10% to $10.1 billion

Stock Market Today: The Dow Jones index rises Wednesday after surprise jobs data. AMD stock and SpaceX plunge on earnings.

Amgen Inc (AMGN) delivers 10% revenue growth driven by key products like Repatha and UPLIZNA, while raising full-year 2026 guidance.

Amgen (NASDAQ:AMGN) reported second-quarter revenue above $10 billion, up 10% from a year earlier, as growth across several key medicines offset competitive pressure on its bone-health franchise. The company raised its full-year revenue and adjusted earnings outlook while continuing to increase spen

Amgen (AMGN) delivered earnings and revenue surprises of +12.32% and +6.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The biotechnology company now expects full-year revenue between $38.2 billion and $39.4 billion, but said it was halting the development of a potential obesity treatment currently in a phase 1 study.